Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis by integrating cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics that improve human health.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/15/2022 | Series D | $236MM | $xx.xx | $126.89B | Alexandria Venture Investments, Bill Gates, Casdin Capital, Dns Capital, Euclidean Capital, Hartford Healthcare Endowment, Illumina Ventures, Lux Capital, Mubadala, Parkwood, Polaris Partners, Stepstone Group, Tao Capital, The Column Group, Two Sigma Ventures | |
Price per Share
$xx.xx
Shares Outstanding
43,302,752
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Bill Gates, Casdin Capital, Dns Capital, Euclidean Capital, Hartford Healthcare Endowment, Illumina Ventures, Lux Capital, Mubadala, Parkwood, Polaris Partners, Stepstone Group, Tao Capital, The Column Group, Two Sigma Ventures
|
||||||
03/25/2020 | Series C | $112.5MM | $xx.xx | $49.65B | Alexandria Venture Investments, Bill Gates, Casdin Capital, Euclidean Capital, Greenspring Associates, Illumina Ventures, Lux Capital, Polaris Partners, The Column Group, Two Sigma Ventures | |
Price per Share
$xx.xx
Shares Outstanding
37,499,994
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Bill Gates, Casdin Capital, Euclidean Capital, Greenspring Associates, Illumina Ventures, Lux Capital, Polaris Partners, The Column Group, Two Sigma Ventures
|
||||||
12/05/2018 | Series B | $86.91MM | $xx.xx | $23.17B | Alexandria Venture Investments, Bill Gates, Euclidean Capital, Illumina Ventures, Lux Capital, Polaris Partners, The Column Group, Two Sigma Ventures | |
Price per Share
$xx.xx
Shares Outstanding
43,454,779
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Bill Gates, Euclidean Capital, Illumina Ventures, Lux Capital, Polaris Partners, The Column Group, Two Sigma Ventures
|
||||||
12/11/2015 | Series A | $44.05MM | $xx.xx | $6.78B | Alexandria Venture Investments, Illumina Ventures, Lux Capital, Polaris Partners, The Column Group | |
Price per Share
$xx.xx
Shares Outstanding
44,050,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Illumina Ventures, Lux Capital, Polaris Partners, The Column Group
|